The city of Durham, North Carolina, currently has 10 active clinical trials seeking participants for Diabetes research studies.
Evaluation of the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy
Recruiting
The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled with insulin therapy. The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita® System compared to a sham. Subjects randomized to the DMR procedure will be followed per protocol till 48 weeks post treatment. Subjects in the Sham... Read More
Gender:
All
Ages:
Between 21 years and 70 years
Trial Updated:
05/31/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Type 2 Diabetes
Effect of Corticosteroid Injections on Blood Glucose
Recruiting
The purpose of this study is to measure the effect of various corticosteroids administered to the shoulder, knee and hip joints in diabetic patients on resultant blood glucose readings.
Gender:
All
Ages:
Between 40 years and 75 years
Trial Updated:
05/22/2024
Locations: Duke Sports Science Institute, Durham, North Carolina
Conditions: Diabetes Mellitus, Steroid Diabetes, Shoulder Osteoarthritis, Knee Osteoarthritis, Adhesive Capsulitis, Hip Osteoarthritis
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Recruiting
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
05/20/2024
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Type2Diabetes, ASCVD
iACT for Eating Disorders in Type 1 Diabetes
Recruiting
This project is a randomized controlled trial of iACT, a novel mHealth intervention for eating disorders in type 1 diabetes (ED-T1DM). Participants will be 128 T1DM patients between the ages of 16-45 with binge-purge EDs, including threshold and subthreshold bulimia nervosa, binge eating disorder and purging disorder. Participants will be randomized to either iACT or Usual Care, and complete assessments at baseline and every 3 months for 9 months. The primary outcome of interest is glycemic cont... Read More
Gender:
All
Ages:
Between 16 years and 50 years
Trial Updated:
05/07/2024
Locations: Duke University, Durham, North Carolina
Conditions: Type 1 Diabetes, Eating Disorders
Onco-primary Care Networking to Support TEAM-based Care
Recruiting
The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second randomization for the intervention group using a dynamic treatment regimen approach. The investigators propose to randomize 800 adults with newly-diagnosed selected cancers treated with curative intent (breast, prostate, colorectal, endometrial, non-small cell lung, and endometrial) and with >1 selected cardiovascular... Read More
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
03/15/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Blood Pressure, Hypertension, Cancer, Cancer, Breast, Cancer of Prostate, Cancer Colorectal, Cancer, Endometrial, Cancer of Head and Neck, Non Small Cell Lung Cancer, CVD - Cardiovascular Disease, Diabetes Mellitus, Hypercholesterolemia, Diabetes, Cancer of Esophagus, Cancer of Liver, Cancer, Renal Cell, Cancer of Pancreas, Cancer Ovaries
CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients
Recruiting
CREST-KT is a single-center, double-blinded, randomized trial of empagliflozin therapy in 72 kidney transplant recipients with (n=36) and without type 2 diabetes (n=36). After evenly dividing patients by type 2 diabetes diagnosis, patients will be randomized 2:1 to empagliflozin 10mg versus placebo.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Kidney Transplant; Complications, Diabetes Mellitus, Type 2
Optimizing In-hospital Use of Evidence-based Therapies for Patients With Cardio-Renal-Metabolic Disease
Recruiting
This study will be a prospective randomized implementation trial for patients hospitalized with heart failure, chronic kidney disease, and/or type 2 diabetes mellitus within Duke University Medical Center. The primary hypothesis is that a virtual quality improvement-based consult intervention will improve the rate of in-hospital evidence-based cardio-renal-metabolic medication use, particularly SGLT2 inhibitor therapy. Approximately 200 patients meeting eligibility criteria will be included in t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Heart Failure, Type 2 Diabetes, Chronic Kidney Diseases
Study of Pregnancy And Neonatal Health (SPAN)
Recruiting
This study will conduct a randomized trial among women with gestational diabetes (GDM). Study of Pregnancy And Neonatal health (SPAN), TIMing of dElivery (TIME) is a randomized trial that will recruit up to 3,450 pregnant women with uncontrolled GDM and randomize the timing of their delivery. Women with GDM who are approached for the trial and are found eligible but do not consent to participating in randomization for delivery will be asked to consent for chart review only (estimated additional... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
09/26/2023
Locations: Duke University Perinatal Research Center, Durham, North Carolina
Conditions: Gestational Diabetes Mellitus
Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US
Recruiting
This study has 3 aims. Aim 1: Identify social determinants of cardiometabolic health and determine facilitators and modifiable barriers in achieving treatment goals. Aim 2: Assess PLWH knowledge, skills, and confidence for self-management of cardiometabolic disorders. Aim 3: Tailor a self-management support and education intervention with stakeholder input to address barriers to achieving treatment goals for cardiometabolic disorders in PLWH at the study sites.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/11/2023
Locations: Duke University - Duke Study Site, Durham, North Carolina
Conditions: Hypertension, Dyslipidemias, Type 2 Diabetes, HIV-1-infection
Eat Well Produce Benefit for Diabetes and Food Insecurity
Recruiting
The goal of this clinical trial is to assess the impact of participation in Eat Well for diabetes patients who are at risk of food insecurity. The main questions it aims to answer are: whether there is a difference in Haemoglobin (Hb) A1c measurements and emergency department (ED) utilization between the Eat Well and control groups up to 18 months post-program completion. whether there are differences in cardiometabolic health-related outcomes for Eat Well participants. Participants in the pro... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/23/2023
Locations: Duke University Health System, Durham, North Carolina
Conditions: Diabetes Mellitus, Food Insecurity